Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $137.0K | $131.0K | $991.0K | $7,529.0K | $11.7M | $10.4M | $6,921.0K | $4,417.0K | $0.0 | $11.5M | $11.5M | $0.0 | $0.0 | $0.0 | $9,835.0K | $136.5M | $164.4M | $188.5M | $245.4M | $305.2M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Insmed Incorporated's last 12-month Revenue is $343.0M, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Insmed Incorporated's Revenue growth was 22.1%. The average annual Revenue growth rates for Insmed Incorporated have been 26.9% over the past three years, 27.8% over the past five years.
Over the last year, Insmed Incorporated's Revenue growth was 22.1%, which is higher than industry growth of 3.0%. It indicates that Insmed Incorporated's Revenue growth is Good.